Controversies and challenges in the current management of nasopharyngeal cancer

References

• Ma J, Cao S. The epidemiology of nasopharyngeal carcinoma. In: Nasopharyngeal Cancer: Multidisciplinary Management. Lu JJ, Cooper JS, Lee AWM (Eds). Springer-Verlag, Heidelberg, Germany, 1–7 (2010).
   Google Scholar
• Wei WI, Sham JST. Nasopharyngeal carcinoma. Lancet365, 2041–2054 (2005).
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J. Clin. Oncol.24(17), 2618–2623 (2006).
   PubMed Web of Science ®Google Scholar
• Chong VF, Ong CK. Nasopharyngeal carcinoma. Eur. J. Radiol.66(3), 437–447 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J. Clin. Oncol.16(4), 1310–1317 (1998).
   PubMed Web of Science ®Google Scholar
• Baujat B, Audry H, Bourhis J et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int. J. Radiat. Oncol. Biol. Phys.64(1), 47–56 (2006).
   PubMed Web of Science ®Google Scholar
• Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J. Clin. Oncol.22(22), 4604–4612 (2004).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am. J. Clin. Oncol.25(3), 219–223 (2002).
   PubMedGoogle Scholar
• Lee AW, Lau WH, Tung SY et al. Hong Kong Nasopharyngeal Cancer Study Group. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J. Clin. Oncol.23(28), 6966–6975 (2005).
   PubMedGoogle Scholar
• Lee AW, Sze WM, Au JS et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int. J. Radiat. Oncol. Biol. Phys.61(4), 1107–1116 (2005).
   PubMed Web of Science ®Google Scholar
• Heng DM, Wee J, Fong KW et al. Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer86(10), 1912–1920 (1999).
   PubMed Web of Science ®Google Scholar
• Chua DT, Sham JST, Kwong DLW et al. Treatment outcome after radiotherapy alone for patients with stage I–II nasopharyngeal carcinoma. Cancer98(1), 74–80 (2003).
   PubMed Web of Science ®Google Scholar
• Tham IWK, Lin S, Pan J, Han L, Lu JJ, Wee J. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIB nasopharyngeal cancer. Am. J. Clin. Oncol.33(3), 294–299 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng SH, Tsai SY, Yen KL et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J. Clin. Oncol.18(10), 2040–2045 (2000).
   PubMed Web of Science ®Google Scholar
• Chua DT, Ma J, Sham JS et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: subgroup analysis of two Phase III trials. Int. J. Radiat. Oncol. Biol. Phys.65(5), 1300–1306 (2006).
   PubMedGoogle Scholar
• Leung TW, Tung SY, Sze WK et al. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck27(7), 555–565 (2005).
   PubMedGoogle Scholar
• Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC. Another way to estimate outcome of advanced nasopharyngeal carcinoma – is concurrent chemoradiotherapy adequate. Int. J. Radiat. Oncol. Biol. Phys.60(1), 156–164 (2004).
   PubMedGoogle Scholar
• Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med.357(17), 1705–1715 (2007).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med.357(17), 1695–1704 (2007).
   PubMed Web of Science ®Google Scholar
• Hui EP, Ma BB, Leung SF et al. Randomized Phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J. Clin. Oncol.27(2), 242–249 (2009).
   PubMed Web of Science ®Google Scholar
• Lee AW, Lau KY, Hung WM et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother. Oncol.87(2), 204–210 (2008).
   PubMedGoogle Scholar
• Lin S, Lu JJ, Han L, Chen Q, Pan J. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer10, 39 (2010).
   PubMed Web of Science ®Google Scholar
• Emami B, Sethi A, Petruzzelli GJ et al. Influence of MRI on target volume delineation and IMRT planning in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.57(2), 481–488 (2003).
   PubMed Web of Science ®Google Scholar
• Ng SH, Chan SC, Yen TC et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur. J. Nucl. Med. Mol. Imaging36(1), 12–22 (2009).
   PubMedGoogle Scholar
• Liang SB, Sun Y, Liu LZ et al. Extension of local disease in nasopharyngeal carcinoma detected by magnetic resonance imaging: improvement of clinical target volume delineation. Int. J. Radiat. Oncol. Biol. Phys.75(3), 742–750 (2009).
   PubMedGoogle Scholar
• Lin S, Pan J, Lu H et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int. J. Radiat. Oncol. Biol. Phys.75(4), 1071–1078 (2009).
   PubMed Web of Science ®Google Scholar
• Tang L, Mao Y, Liu L et al. The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging. Cancer115(3), 680–688 (2009).
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhu G, Lu J et al. Is elective irradiation to the lower neck necessary for N0 nasopharyngeal carcinoma? Int. J. Radiat. Oncol. Biol. Phys.77(5), 1397–1402 (2009).
   Google Scholar
• van Herk M, Remeijer P, Lebesque JV. Inclusion of geometric uncertainties in treatment plan evaluation. Int. J. Radiat. Oncol. Biol. Phys.52(5), 1407–1422 (2002).
   PubMedGoogle Scholar
• Siebers JV, Keall PJ, Wu Q, Williamson JF, Schmidt-Ullrich RK. Effect of patient setup errors on simultaneously integrated boost head and neck IMRT treatment plans. Int. J. Radiat. Oncol. Biol. Phys.63(2), 422–433 (2005).
   PubMedGoogle Scholar
• Manning MA, Wu Q, Cardinale RM et al. The effect of setup uncertainty on normal tissue sparing with IMRT for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys.51(5), 1400–1409 (2001).
   PubMed Web of Science ®Google Scholar
• Hurkmans CW, Remeijer P, Lebesque JV, Mijnheer BJ. Set-up verification using portal imaging; review of current clinical practice. Radiother. Oncol.58(2), 105–120 (2001).
   PubMed Web of Science ®Google Scholar
• O’Daniel JC, Garden AS, Schwartz DL et al. Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get? Int. J. Radiat. Oncol. Biol. Phys.69(4), 1290–1296 (2007).
   PubMed Web of Science ®Google Scholar
• Den RB, Doemer A, Kubicek G et al. Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensity-modulated radiotherapy: a prospective study. Int. J. Radiat. Oncol. Biol. Phys.76(5), 1353–1359 (2010).
   PubMed Web of Science ®Google Scholar
• Bhide SA, Davies M, Burke K et al. Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. Int. J. Radiat. Oncol. Biol. Phys.76(5), 1360–1368 (2010).
   PubMed Web of Science ®Google Scholar
• Xia P, Le QT. Head and neck cancers. In: Image-Guided and Adaptive Radiation Therapy. Timmerman R, Xing L (Eds). Wolters Kluwer, Lippincott Williams and Wilkins, PA, USA, 183–190 (2010).
   Google Scholar
• Baxi S, Park E, Chong V, Chung HT. Temporal changes in IMRT contouring of organs at risk for nasopharyngeal carcinoma – the learning curve blues and a tool that could help. Technol. Cancer. Res. Treat.8(2), 131–140 (2009).
   PubMedGoogle Scholar
• Leong CN, Shakespeare TP, Mukherjee RK et al. Efficacy of an integrated continuing medical education (CME) and quality improvement (QI) program on radiation oncologist (RO) clinical practice. Int. J. Radiat. Oncol. Biol. Phys.66(5), 1457–1460 (2006).
   PubMed Web of Science ®Google Scholar
• Pow EH, Kwong DL, McMillan AS et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int. J. Radiat. Oncol. Biol. Phys.66(4), 981–991 (2006).
   PubMed Web of Science ®Google Scholar
• Kam MK, Leung SF, Zee B et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J. Clin. Oncol.25(31), 4873–4879 (2007).
   PubMed Web of Science ®Google Scholar
• Murdoch-Kinch CA, Kim HM, Vineberg KA, Ship JA, Eisbruch A. Dose–effect relationships for the submandibular glands and implications for their sparing by intensity modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.72(2), 373–382 (2008).
   PubMed Web of Science ®Google Scholar
• Rancati T, Schwarz M, Allen AM et al. Radiation dose–volume effects in the larynx and pharynx. Int. J. Radiat. Oncol. Biol. Phys.76(3 Suppl.), S64–S69 (2010).
   PubMed Web of Science ®Google Scholar
• Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J. Clin. Oncol.24(12), 1904–1909 (2006).
   PubMed Web of Science ®Google Scholar
• Monroe AT, Reddy SC, Gibbs GL, White GA, Peddada AV. Factors associated with radiation-induced nausea and vomiting in head and neck cancer patients treated with intensity modulated radiation therapy. Radiother. Oncol.87(2), 188–194 (2008).
   PubMed Web of Science ®Google Scholar
• Lee N, Harris J, Garden AS et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group Phase II trial 0225. J. Clin. Oncol.27(22), 3684–3690 (2009).
   PubMed Web of Science ®Google Scholar
• Cannon DM, Lee NY. Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys.70(3), 660–665 (2008).
   PubMedGoogle Scholar
• Krishna SM, James S, Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res.115(1), 85–90 (2006).
   PubMedGoogle Scholar
• Ma B, Leung SF, Kam MK et al. A Phase II study of concurrent cetuximab–cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). J. Clin. Oncol.26(Suppl.), 6055 (2008).
   Google Scholar
• Pan JJ, Zhang SW, Chen CB et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J. Clin. Oncol.27(5), 799–804 (2009).
   PubMed Web of Science ®Google Scholar
• Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl. J. Med.350(24), 2461–2470 (2004).
   PubMed Web of Science ®Google Scholar
• Leung SF, Chan ATC, Zee B et al. Pretherapy quantitative measurement of circulating Epstein–Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer98(2), 288–291 (2003).
   PubMed Web of Science ®Google Scholar
• Lin JC, Wang WY, Liang WM et al. Long-term prognostic effects of plasma Epstein–Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys.68(5), 1342–1348 (2007).
   PubMedGoogle Scholar
• Lin JC. Prognostic factors in nasopharyngeal cancer. In: Nasopharyngeal Cancer: Multidisciplinary Management. Lu JJ, Cooper JS, Lee AWM (Eds). Springer-Verlag, Heidelberg, Germany, 95–136 (2010).
   Google Scholar
• Kwong DL, Sham JS, Leung LH et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.64(2), 374–381 (2006).
   PubMedGoogle Scholar
• Hara W, Loo BW Jr, Goffinet DR et al. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.71(2), 393–400 (2008).
   PubMed Web of Science ®Google Scholar
• Lee N, Xia P, Quivey JM et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int. J. Radiat. Oncol. Biol. Phys.53(1), 12–22 (2002).
   PubMed Web of Science ®Google Scholar
• Liu MT, Hsieh CY, Chang TH et al. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn. J. Clin. Oncol.33(10), 501–508 (2003).
   PubMedGoogle Scholar
• Kam MK, Teo PM, Chau RM et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int. J. Radiat. Oncol. Biol. Phys.60(5), 1440–1450 (2004).
   PubMed Web of Science ®Google Scholar
• Kwong DL, Pow EH, Sham JS et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer101(7), 1584–1593 (2004).
   PubMed Web of Science ®Google Scholar
• Wolden SL, Chen WC, Pfister DG et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan–Kettering experience. Int. J. Radiat. Oncol. Biol. Phys.64(1), 57–62 (2006).
   PubMed Web of Science ®Google Scholar
• Tham IW, Hee SW, Yeo RM et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy – the National Cancer Centre Singapore Experience. Int. J. Radiat. Oncol. Biol. Phys.75(5), 1481–1486 (2009).
   PubMed Web of Science ®Google Scholar
• Lin S, Pan J, Han L, Zhang X, Liao X, Lu JJ. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int. J. Radiat. Oncol. Biol. Phys.75(4), 1071–1078 (2009).
   PubMed Web of Science ®Google Scholar
• Wee J, Tan EH, Tai BC et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J. Clin. Oncol.23(27), 6730–6738 (2005).
   PubMed Web of Science ®Google Scholar
• Lee AW, Tung SY, Chan AT et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.66(1), 142–151 (2006).
   PubMedGoogle Scholar
• Chen Y, Liu MZ, Liang SB et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int. J. Radiat. Oncol. Biol. Phys.71(5), 1356–1364 (2008).
   PubMed Web of Science ®Google Scholar
• Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J. Clin. Oncol.21(4), 631–637 (2003).
   PubMed Web of Science ®Google Scholar
• Chan AT, Teo PM, Ngan RK et al. Concurrent chemotherapy–radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a Phase III randomized trial. J. Clin. Oncol.20(8), 2038–2044 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao C, Peng PJ et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J. Clin. Oncol.23(33), 8461–8468 (2005).
   PubMedGoogle Scholar
• Kwong DL, Sham JS, Au GK et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J. Clin. Oncol.22(13), 2643–2653 (2004).
   PubMed Web of Science ®Google Scholar
• Cvitkovic E, Eschwege F, Rahal M et al. Preliminary results of trial comparing neoadjuvant chemotherapy (Cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in Stage IV (≥N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression free survival. Int. J. Radiat. Oncol. Biol. Phys.35(3), 463– 469 (1996).
   PubMedGoogle Scholar
• Chua DT, Sham JS, Choy D et al. Preliminary report of the Asian–Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian–Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer83(11), 2270–2283 (1998).
   PubMed Web of Science ®Google Scholar
• Hareyama M, Sakata K, Shirato H et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer94(8), 2217–2223 (2002).
   PubMed Web of Science ®Google Scholar
• Ma J, Mai HQ, Hong MH et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J. Clin. Oncol.19(5), 1350–1357 (2001).
   PubMed Web of Science ®Google Scholar
• Chan AT, Teo PM, Leung TW et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.33(3), 569–577 (1995).
   PubMedGoogle Scholar
• Rossi A, Molinari R, Boracchi P et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J. Clin. Oncol.6(9), 1401–1410 (1988).
   PubMed Web of Science ®Google Scholar
• Chi KH, Chang YC, Guo WY et al. A Phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int. J. Radiat. Oncol. Biol. Phys.52(5), 1238–1244 (2002).
   PubMed Web of Science ®Google Scholar